Cancer Biology & Medicine最新文献_第6页

Drug clinical trials on high-grade gliomas: challenges and hopes. 高级别胶质瘤药物临床试验：挑战与希望。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2023.0364

Mengqian Huang, Shenglan Li, Parker Li, Zhuang Kang, Botao Zhang, Wenbin Li

引用次数: 0

DNA methylation biomarkers for early detection of gastric and colorectal cancers. 用于早期检测胃癌和结肠直肠癌的 DNA 甲基化生物标记物。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2023.0443

Xianchun Gao, Hui Liu, Jun Yu, Yongzhan Nie

引用次数: 0

Insight into the evolution of breast cancer driven by genetic alterations. 洞察由基因改变驱动的乳腺癌演变。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2023.0454

Canbin Fang, Xueqi Fan, Wanling Lin, Guojun Zhang

引用次数: 0

Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? 无化疗放疗联合免疫检查点抑制剂：治疗局部晚期非小细胞肺癌的新方案？

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2023.0402

Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng

{"title":"Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?","authors":"Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng","doi":"10.20892/j.issn.2095-3941.2023.0402","DOIUrl":"10.20892/j.issn.2095-3941.2023.0402","url":null,"abstract":"Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current therapeutic landscape and resistance mechanisms to larotrectinib. 拉罗替尼目前的治疗前景和耐药机制。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2023.0471

Weiji Xie, Jiaqian Xu, Suying Lu, Yizhuo Zhang

引用次数: 0

Neutrophils in the era of single-cell RNA sequencing: functions and targeted therapies in cancer. 单细胞 RNA 测序时代的中性粒细胞：癌症的功能和靶向治疗。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-02-05 DOI: 10.20892/j.issn.2095-3941.2024.0012

Jing Qin, Feng Wei, Xiubao Ren

引用次数: 0

Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. 基于组织病理学分化和 Ki-67 的胰腺导管腺癌恶性程度的预后意义

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-01-03 DOI: 10.20892/j.issn.2095-3941.2023.0363

Yuexiang Liang, Guannan Sheng, Yu Guo, Yiping Zou, Hanhan Guo, Zhifei Li, Shaofei Chang, Quan Man, Song Gao, Jihui Hao

{"title":"Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma.","authors":"Yuexiang Liang, Guannan Sheng, Yu Guo, Yiping Zou, Hanhan Guo, Zhifei Li, Shaofei Chang, Quan Man, Song Gao, Jihui Hao","doi":"10.20892/j.issn.2095-3941.2023.0363","DOIUrl":"10.20892/j.issn.2095-3941.2023.0363","url":null,"abstract":"Objective: Tumor cell malignancy is indicated by histopathological differentiation and cell proliferation. Ki-67, an indicator of cellular proliferation, has been used for tumor grading and classification in breast cancer and neuroendocrine tumors. However, its prognostic significance in pancreatic ductal adenocarcinoma (PDAC) remains uncertain.Methods: Patients who underwent radical pancreatectomy for PDAC were retrospectively enrolled, and relevant prognostic factors were examined. Grade of malignancy (GOM), a novel index based on histopathological differentiation and Ki-67, is proposed, and its clinical significance was evaluated.Results: The optimal threshold for Ki-67 was determined to be 30%. Patients with a Ki-67 expression level > 30% rather than ≤ 30% had significantly shorter 5-year overall survival (OS) and recurrence-free survival (RFS). In multivariate analysis, both histopathological differentiation and Ki-67 were identified as independent prognostic factors for OS and RFS. The GOM was used to independently stratify OS and RFS into 3 tiers, regardless of TNM stage and other established prognostic factors. The tumor-node-metastasis-GOM stage was used to stratify survival into 5 distinct tiers, and surpassed the predictive performance of TNM stage for OS and RFS.Conclusions: Ki-67 is a valuable prognostic indicator for PDAC. Inclusion of the GOM in the TNM staging system may potentially enhance prognostic accuracy for PDAC.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies. cGAS-STING 信号在癌症免疫疗法策略中的新机制和意义。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-01-03 DOI: 10.20892/j.issn.2095-3941.2023.0440

Jiawen Zhang, Sihui Yu, Qiao Peng, Ping Wang, Lan Fang

{"title":"Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.","authors":"Jiawen Zhang, Sihui Yu, Qiao Peng, Ping Wang, Lan Fang","doi":"10.20892/j.issn.2095-3941.2023.0440","DOIUrl":"10.20892/j.issn.2095-3941.2023.0440","url":null,"abstract":"The intricate interplay between the human immune system and cancer development underscores the central role of immunotherapy in cancer treatment. Within this landscape, the innate immune system, a critical sentinel protecting against tumor incursion, is a key player. The cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway has been found to be a linchpin of innate immunity: activation of this signaling pathway orchestrates the production of type I interferon (IFN-α/β), thus fostering the maturation, differentiation, and mobilization of immune effectors in the tumor microenvironment. Furthermore, STING activation facilitates the release and presentation of tumor antigens, and therefore is an attractive target for cancer immunotherapy. Current strategies to activate the STING pathway, including use of pharmacological agonists, have made substantial advancements, particularly when combined with immune checkpoint inhibitors. These approaches have shown promise in preclinical and clinical settings, by enhancing patient survival rates. This review describes the evolving understanding of the cGAS-STING pathway's involvement in tumor biology and therapy. Moreover, this review explores classical and non-classical STING agonists, providing insights into their mechanisms of action and potential for optimizing immunotherapy strategies. Despite challenges and complexities, the cGAS-STING pathway, a promising avenue for enhancing cancer treatment efficacy, has the potential to revolutionize patient outcomes.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status of early gastric cancer screening research. 早期胃癌筛查研究现状。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2024-01-02 DOI: 10.20892/j.issn.2095-3941.2023.0377

Can Hu, Li Yuan, Xiangdong Cheng

引用次数: 0

Cervical cancer prevention in China: where are we now, and what's next? 中国的宫颈癌预防：我们现在在哪里？

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2024-01-02 DOI: 10.20892/j.issn.2095-3941.2023.0432

Huijiao Yan, Qiankun Wang, Youlin Qiao

引用次数: 0